MA49472A - Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole - Google Patents
Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrroleInfo
- Publication number
- MA49472A MA49472A MA049472A MA49472A MA49472A MA 49472 A MA49472 A MA 49472A MA 049472 A MA049472 A MA 049472A MA 49472 A MA49472 A MA 49472A MA 49472 A MA49472 A MA 49472A
- Authority
- MA
- Morocco
- Prior art keywords
- preparation process
- intermediate preparation
- derivative intermediate
- methoxypyrrole derivative
- methoxypyrrole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170078745A KR102233455B1 (ko) | 2017-06-21 | 2017-06-21 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| PCT/KR2018/006989 WO2018236153A1 (fr) | 2017-06-21 | 2018-06-21 | Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA49472A true MA49472A (fr) | 2020-04-29 |
| MA49472B1 MA49472B1 (fr) | 2022-01-31 |
Family
ID=64735783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA49472A MA49472B1 (fr) | 2017-06-21 | 2018-06-21 | Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11345660B2 (fr) |
| EP (1) | EP3642181B1 (fr) |
| JP (1) | JP6799178B2 (fr) |
| KR (1) | KR102233455B1 (fr) |
| CN (1) | CN110582482B (fr) |
| AU (1) | AU2018288933B2 (fr) |
| BR (1) | BR112019027323A2 (fr) |
| CA (1) | CA3061713C (fr) |
| CL (1) | CL2019003450A1 (fr) |
| CO (1) | CO2019012689A2 (fr) |
| DO (1) | DOP2019000291A (fr) |
| EC (1) | ECSP19081847A (fr) |
| ES (1) | ES2901701T3 (fr) |
| HR (1) | HRP20211819T1 (fr) |
| HU (1) | HUE057666T2 (fr) |
| JO (1) | JOP20190265B1 (fr) |
| MA (1) | MA49472B1 (fr) |
| MY (1) | MY188800A (fr) |
| NZ (1) | NZ758770A (fr) |
| PE (1) | PE20210151A1 (fr) |
| PH (1) | PH12019502865A1 (fr) |
| PL (1) | PL3642181T3 (fr) |
| PT (1) | PT3642181T (fr) |
| RS (1) | RS62564B1 (fr) |
| RU (1) | RU2737470C1 (fr) |
| SA (1) | SA519410407B1 (fr) |
| SG (1) | SG11201911164WA (fr) |
| SI (1) | SI3642181T1 (fr) |
| TN (1) | TN2019000301A1 (fr) |
| WO (1) | WO2018236153A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102081920B1 (ko) | 2016-03-25 | 2020-02-26 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
| KR102233455B1 (ko) * | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| US10789690B2 (en) * | 2018-03-07 | 2020-09-29 | Adobe Inc. | Masking non-public content |
| KR102126576B1 (ko) | 2018-09-19 | 2020-06-24 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
| CN109867617A (zh) * | 2019-04-03 | 2019-06-11 | 南京格亚医药科技有限公司 | 一种4-甲氧基吡咯中间体的制备方法 |
| CN112094219B (zh) * | 2020-09-10 | 2022-08-05 | 广东莱佛士制药技术有限公司 | 一种制备钾离子竞争性阻滞剂中间体的方法 |
| KR20240127136A (ko) * | 2023-02-15 | 2024-08-22 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
| CN117326961B (zh) * | 2023-09-27 | 2024-05-03 | 安徽峆一药业股份有限公司 | 一种非苏拉赞中间体的绿色合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622948A (en) | 1994-12-01 | 1997-04-22 | Syntex (U.S.A.) Inc. | Pyrrole pyridazine and pyridazinone anti-inflammatory agents |
| ES2402362T3 (es) | 2004-09-30 | 2013-05-03 | Takeda Pharmaceutical Company Limited | Inhibidores de la bomba de protones |
| PE20110009A1 (es) | 2005-08-30 | 2011-01-31 | Takeda Pharmaceutical | Derivados de pirrol como inhibidores de la secrecion acida |
| JP5248528B2 (ja) | 2007-02-02 | 2013-07-31 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｎｓ疾患用のｔａａｒ１リガンドとしての新規２−アミノオキサゾリン |
| WO2009137657A1 (fr) | 2008-05-08 | 2009-11-12 | Bristol-Myers Squibb Company | Dérivés du 2-arylglycinamide |
| US8895558B2 (en) * | 2008-10-02 | 2014-11-25 | Green Cross Corporation | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders |
| KR101613245B1 (ko) | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| KR20170113040A (ko) * | 2016-03-25 | 2017-10-12 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염 |
| WO2017164575A1 (fr) | 2016-03-25 | 2017-09-28 | Daewoong Pharmaceutical Co.,Ltd. | Nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine |
| KR102081920B1 (ko) * | 2016-03-25 | 2020-02-26 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
| KR102233456B1 (ko) | 2017-05-31 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102233455B1 (ko) * | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102126576B1 (ko) * | 2018-09-19 | 2020-06-24 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
-
2017
- 2017-06-21 KR KR1020170078745A patent/KR102233455B1/ko active IP Right Grant
-
2018
- 2018-06-21 HR HRP20211819TT patent/HRP20211819T1/hr unknown
- 2018-06-21 CN CN201880029597.9A patent/CN110582482B/zh active Active
- 2018-06-21 MY MYPI2019006395A patent/MY188800A/en unknown
- 2018-06-21 RS RS20211408A patent/RS62564B1/sr unknown
- 2018-06-21 NZ NZ758770A patent/NZ758770A/en unknown
- 2018-06-21 WO PCT/KR2018/006989 patent/WO2018236153A1/fr unknown
- 2018-06-21 AU AU2018288933A patent/AU2018288933B2/en active Active
- 2018-06-21 US US16/608,924 patent/US11345660B2/en active Active
- 2018-06-21 CA CA3061713A patent/CA3061713C/fr active Active
- 2018-06-21 EP EP18821303.7A patent/EP3642181B1/fr active Active
- 2018-06-21 PE PE2019002402A patent/PE20210151A1/es unknown
- 2018-06-21 PT PT188213037T patent/PT3642181T/pt unknown
- 2018-06-21 MA MA49472A patent/MA49472B1/fr unknown
- 2018-06-21 ES ES18821303T patent/ES2901701T3/es active Active
- 2018-06-21 JO JOP/2019/0265A patent/JOP20190265B1/ar active
- 2018-06-21 PL PL18821303T patent/PL3642181T3/pl unknown
- 2018-06-21 JP JP2019563427A patent/JP6799178B2/ja active Active
- 2018-06-21 RU RU2019135250A patent/RU2737470C1/ru active
- 2018-06-21 HU HUE18821303A patent/HUE057666T2/hu unknown
- 2018-06-21 TN TNP/2019/000301A patent/TN2019000301A1/en unknown
- 2018-06-21 SG SG11201911164WA patent/SG11201911164WA/en unknown
- 2018-06-21 SI SI201830482T patent/SI3642181T1/sl unknown
- 2018-06-21 BR BR112019027323-9A patent/BR112019027323A2/pt unknown
-
2019
- 2019-10-29 SA SA519410407A patent/SA519410407B1/ar unknown
- 2019-11-14 CO CONC2019/0012689A patent/CO2019012689A2/es unknown
- 2019-11-14 DO DO2019000291A patent/DOP2019000291A/es unknown
- 2019-11-15 EC ECSENADI201981847A patent/ECSP19081847A/es unknown
- 2019-11-26 CL CL2019003450A patent/CL2019003450A1/es unknown
- 2019-12-18 PH PH12019502865A patent/PH12019502865A1/en unknown
-
2022
- 2022-04-29 US US17/732,804 patent/US20220259146A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49472A (fr) | Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole | |
| MA50517A (fr) | Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole | |
| MA54253A (fr) | Procédé de préparation de dérivés de 2-chloro-4-hétéroaryl-pyridimidines | |
| MA52906A (fr) | Procédé de préparation d'amg 416 | |
| HK1256795A1 (zh) | 可用於治療自身免疫疾病的二吡唑基衍生物 | |
| MA48723A (fr) | Procédé de production d'anticorps multispécifiques | |
| DK3635101T3 (da) | Manipulerede ligasevarianter | |
| MA48798A (fr) | Procédé de production d'ozanimod | |
| MA52795A (fr) | Dérivé de carbamoylpyridone polycyclique | |
| MA52802A (fr) | Dérivé de pyridone polycyclique | |
| MA50169A (fr) | Procédé de production d'un électrocatalyseur | |
| MA42423A (fr) | Procédé de préparation d'un revêtement | |
| MA50796A (fr) | Procédé de décomposition de phosphogypse | |
| IL260465B (en) | A process for preparing an antibody-rifamycin conjugate | |
| IL267508B (en) | A process for the preparation of 2-pyridylethyl carboxamide derivatives | |
| MA54396A (fr) | Procédé de préparation de n-phénylpyrazole-1-carboxamides | |
| FR3038312B1 (fr) | Procede de preparation de polyols | |
| MA41790A (fr) | Dérivé de morphinane | |
| FR3048968B1 (fr) | Procede de preparation d'alkylamines | |
| MA42264A (fr) | Procédé de préparation d'oltipraz | |
| MA49555A (fr) | Procédé amélioré de préparation d'imetelstat | |
| DK3512518T3 (da) | Buprenophinformuleringer med langvarig frigivelse | |
| MA51339A (fr) | Procédé de préparation de composés pyrimidinyl-4-aminopyrazole | |
| FR3049599B1 (fr) | Procede de preparation de l'hexafluorobutadiene. | |
| PL3723479T3 (pl) | Sposoby produkcji sterylnych ryb |